nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—HTR2B—Sorafenib—liver cancer	0.142	0.273	CbGbCtD
Aripiprazole—HTR2C—Sorafenib—liver cancer	0.0926	0.178	CbGbCtD
Aripiprazole—CYP3A7—Sorafenib—liver cancer	0.0604	0.116	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.0604	0.116	CbGbCtD
Aripiprazole—CYP3A5—Sorafenib—liver cancer	0.0453	0.0869	CbGbCtD
Aripiprazole—ABCB1—Sorafenib—liver cancer	0.0295	0.0565	CbGbCtD
Aripiprazole—CYP2D6—Sorafenib—liver cancer	0.0278	0.0533	CbGbCtD
Aripiprazole—ABCB1—Doxorubicin—liver cancer	0.0179	0.0343	CbGbCtD
Aripiprazole—CYP3A4—Sorafenib—liver cancer	0.0177	0.0339	CbGbCtD
Aripiprazole—CYP2D6—Doxorubicin—liver cancer	0.0168	0.0323	CbGbCtD
Aripiprazole—CYP3A4—Doxorubicin—liver cancer	0.0107	0.0206	CbGbCtD
Aripiprazole—Dysphagia—Epirubicin—liver cancer	0.000249	0.00074	CcSEcCtD
Aripiprazole—Dehydration—Doxorubicin—liver cancer	0.000248	0.000737	CcSEcCtD
Aripiprazole—Eosinophilia—Epirubicin—liver cancer	0.000247	0.000733	CcSEcCtD
Aripiprazole—Liver function test abnormal—Doxorubicin—liver cancer	0.000246	0.000732	CcSEcCtD
Aripiprazole—Dry skin—Doxorubicin—liver cancer	0.000245	0.000726	CcSEcCtD
Aripiprazole—Pancreatitis—Epirubicin—liver cancer	0.000244	0.000726	CcSEcCtD
Aripiprazole—Vomiting—Sorafenib—liver cancer	0.000244	0.000724	CcSEcCtD
Aripiprazole—Abdominal pain upper—Doxorubicin—liver cancer	0.000244	0.000724	CcSEcCtD
Aripiprazole—Orthostatic hypotension—Doxorubicin—liver cancer	0.000244	0.000724	CcSEcCtD
Aripiprazole—Hypokalaemia—Doxorubicin—liver cancer	0.000243	0.000721	CcSEcCtD
Aripiprazole—Angina pectoris—Epirubicin—liver cancer	0.000243	0.000721	CcSEcCtD
Aripiprazole—Rash—Sorafenib—liver cancer	0.000242	0.000718	CcSEcCtD
Aripiprazole—Dermatitis—Sorafenib—liver cancer	0.000242	0.000718	CcSEcCtD
Aripiprazole—Breast disorder—Doxorubicin—liver cancer	0.000241	0.000716	CcSEcCtD
Aripiprazole—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00024	0.000714	CcSEcCtD
Aripiprazole—Headache—Sorafenib—liver cancer	0.00024	0.000714	CcSEcCtD
Aripiprazole—Nasopharyngitis—Doxorubicin—liver cancer	0.000239	0.000709	CcSEcCtD
Aripiprazole—Gastritis—Doxorubicin—liver cancer	0.000236	0.000701	CcSEcCtD
Aripiprazole—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000235	0.000699	CcSEcCtD
Aripiprazole—Muscular weakness—Doxorubicin—liver cancer	0.000235	0.000699	CcSEcCtD
Aripiprazole—Dysuria—Epirubicin—liver cancer	0.000233	0.000692	CcSEcCtD
Aripiprazole—Neutropenia—Epirubicin—liver cancer	0.000233	0.000692	CcSEcCtD
Aripiprazole—Abdominal distension—Doxorubicin—liver cancer	0.000232	0.00069	CcSEcCtD
Aripiprazole—Upper respiratory tract infection—Epirubicin—liver cancer	0.000232	0.000688	CcSEcCtD
Aripiprazole—Asthma—Doxorubicin—liver cancer	0.000231	0.000685	CcSEcCtD
Aripiprazole—Influenza—Doxorubicin—liver cancer	0.000231	0.000685	CcSEcCtD
Aripiprazole—Dysphagia—Doxorubicin—liver cancer	0.000231	0.000685	CcSEcCtD
Aripiprazole—Pollakiuria—Epirubicin—liver cancer	0.00023	0.000684	CcSEcCtD
Aripiprazole—Eosinophilia—Doxorubicin—liver cancer	0.000228	0.000678	CcSEcCtD
Aripiprazole—Nausea—Sorafenib—liver cancer	0.000228	0.000677	CcSEcCtD
Aripiprazole—Photosensitivity reaction—Epirubicin—liver cancer	0.000228	0.000676	CcSEcCtD
Aripiprazole—Weight increased—Epirubicin—liver cancer	0.000227	0.000674	CcSEcCtD
Aripiprazole—Pancreatitis—Doxorubicin—liver cancer	0.000226	0.000672	CcSEcCtD
Aripiprazole—Weight decreased—Epirubicin—liver cancer	0.000226	0.00067	CcSEcCtD
Aripiprazole—Hyperglycaemia—Epirubicin—liver cancer	0.000225	0.000668	CcSEcCtD
Aripiprazole—Angina pectoris—Doxorubicin—liver cancer	0.000225	0.000667	CcSEcCtD
Aripiprazole—Pneumonia—Epirubicin—liver cancer	0.000224	0.000664	CcSEcCtD
Aripiprazole—Infestation NOS—Epirubicin—liver cancer	0.000222	0.00066	CcSEcCtD
Aripiprazole—Infestation—Epirubicin—liver cancer	0.000222	0.00066	CcSEcCtD
Aripiprazole—Renal failure—Epirubicin—liver cancer	0.000218	0.000649	CcSEcCtD
Aripiprazole—Neuropathy peripheral—Epirubicin—liver cancer	0.000218	0.000647	CcSEcCtD
Aripiprazole—Jaundice—Epirubicin—liver cancer	0.000217	0.000643	CcSEcCtD
Aripiprazole—Stomatitis—Epirubicin—liver cancer	0.000217	0.000643	CcSEcCtD
Aripiprazole—Urinary tract infection—Epirubicin—liver cancer	0.000216	0.000642	CcSEcCtD
Aripiprazole—Conjunctivitis—Epirubicin—liver cancer	0.000216	0.000642	CcSEcCtD
Aripiprazole—Dysuria—Doxorubicin—liver cancer	0.000216	0.000641	CcSEcCtD
Aripiprazole—Neutropenia—Doxorubicin—liver cancer	0.000216	0.000641	CcSEcCtD
Aripiprazole—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000214	0.000637	CcSEcCtD
Aripiprazole—Sweating—Epirubicin—liver cancer	0.000213	0.000633	CcSEcCtD
Aripiprazole—Pollakiuria—Doxorubicin—liver cancer	0.000213	0.000633	CcSEcCtD
Aripiprazole—Haematuria—Epirubicin—liver cancer	0.000212	0.000629	CcSEcCtD
Aripiprazole—Photosensitivity reaction—Doxorubicin—liver cancer	0.000211	0.000625	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Epirubicin—liver cancer	0.00021	0.000624	CcSEcCtD
Aripiprazole—Weight increased—Doxorubicin—liver cancer	0.00021	0.000623	CcSEcCtD
Aripiprazole—Epistaxis—Epirubicin—liver cancer	0.00021	0.000623	CcSEcCtD
Aripiprazole—Weight decreased—Doxorubicin—liver cancer	0.000209	0.00062	CcSEcCtD
Aripiprazole—Sinusitis—Epirubicin—liver cancer	0.000209	0.000619	CcSEcCtD
Aripiprazole—Hyperglycaemia—Doxorubicin—liver cancer	0.000208	0.000618	CcSEcCtD
Aripiprazole—Agranulocytosis—Epirubicin—liver cancer	0.000207	0.000616	CcSEcCtD
Aripiprazole—Pneumonia—Doxorubicin—liver cancer	0.000207	0.000614	CcSEcCtD
Aripiprazole—Infestation NOS—Doxorubicin—liver cancer	0.000206	0.000611	CcSEcCtD
Aripiprazole—Infestation—Doxorubicin—liver cancer	0.000206	0.000611	CcSEcCtD
Aripiprazole—Bradycardia—Epirubicin—liver cancer	0.000203	0.000603	CcSEcCtD
Aripiprazole—Renal failure—Doxorubicin—liver cancer	0.000202	0.0006	CcSEcCtD
Aripiprazole—Neuropathy peripheral—Doxorubicin—liver cancer	0.000202	0.000599	CcSEcCtD
Aripiprazole—Haemoglobin—Epirubicin—liver cancer	0.000201	0.000596	CcSEcCtD
Aripiprazole—Jaundice—Doxorubicin—liver cancer	0.0002	0.000595	CcSEcCtD
Aripiprazole—Stomatitis—Doxorubicin—liver cancer	0.0002	0.000595	CcSEcCtD
Aripiprazole—Rhinitis—Epirubicin—liver cancer	0.0002	0.000594	CcSEcCtD
Aripiprazole—Urinary tract infection—Doxorubicin—liver cancer	0.0002	0.000594	CcSEcCtD
Aripiprazole—Conjunctivitis—Doxorubicin—liver cancer	0.0002	0.000594	CcSEcCtD
Aripiprazole—Haemorrhage—Epirubicin—liver cancer	0.0002	0.000593	CcSEcCtD
Aripiprazole—Hepatitis—Epirubicin—liver cancer	0.0002	0.000593	CcSEcCtD
Aripiprazole—Hypoaesthesia—Epirubicin—liver cancer	0.000199	0.00059	CcSEcCtD
Aripiprazole—Pharyngitis—Epirubicin—liver cancer	0.000198	0.000588	CcSEcCtD
Aripiprazole—Sweating—Doxorubicin—liver cancer	0.000197	0.000586	CcSEcCtD
Aripiprazole—Urinary tract disorder—Epirubicin—liver cancer	0.000197	0.000585	CcSEcCtD
Aripiprazole—Oedema peripheral—Epirubicin—liver cancer	0.000197	0.000584	CcSEcCtD
Aripiprazole—Haematuria—Doxorubicin—liver cancer	0.000196	0.000582	CcSEcCtD
Aripiprazole—Connective tissue disorder—Epirubicin—liver cancer	0.000196	0.000582	CcSEcCtD
Aripiprazole—Urethral disorder—Epirubicin—liver cancer	0.000196	0.000581	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Doxorubicin—liver cancer	0.000194	0.000578	CcSEcCtD
Aripiprazole—Epistaxis—Doxorubicin—liver cancer	0.000194	0.000576	CcSEcCtD
Aripiprazole—Sinusitis—Doxorubicin—liver cancer	0.000193	0.000573	CcSEcCtD
Aripiprazole—Visual impairment—Epirubicin—liver cancer	0.000192	0.000571	CcSEcCtD
Aripiprazole—Agranulocytosis—Doxorubicin—liver cancer	0.000192	0.00057	CcSEcCtD
Aripiprazole—Bradycardia—Doxorubicin—liver cancer	0.000188	0.000558	CcSEcCtD
Aripiprazole—Eye disorder—Epirubicin—liver cancer	0.000186	0.000554	CcSEcCtD
Aripiprazole—Tinnitus—Epirubicin—liver cancer	0.000186	0.000552	CcSEcCtD
Aripiprazole—Haemoglobin—Doxorubicin—liver cancer	0.000186	0.000551	CcSEcCtD
Aripiprazole—Flushing—Epirubicin—liver cancer	0.000185	0.00055	CcSEcCtD
Aripiprazole—Cardiac disorder—Epirubicin—liver cancer	0.000185	0.00055	CcSEcCtD
Aripiprazole—Rhinitis—Doxorubicin—liver cancer	0.000185	0.00055	CcSEcCtD
Aripiprazole—Haemorrhage—Doxorubicin—liver cancer	0.000185	0.000548	CcSEcCtD
Aripiprazole—Hepatitis—Doxorubicin—liver cancer	0.000185	0.000548	CcSEcCtD
Aripiprazole—Hypoaesthesia—Doxorubicin—liver cancer	0.000184	0.000546	CcSEcCtD
Aripiprazole—Pharyngitis—Doxorubicin—liver cancer	0.000183	0.000544	CcSEcCtD
Aripiprazole—Urinary tract disorder—Doxorubicin—liver cancer	0.000182	0.000541	CcSEcCtD
Aripiprazole—Oedema peripheral—Doxorubicin—liver cancer	0.000182	0.00054	CcSEcCtD
Aripiprazole—Connective tissue disorder—Doxorubicin—liver cancer	0.000181	0.000539	CcSEcCtD
Aripiprazole—Angiopathy—Epirubicin—liver cancer	0.000181	0.000538	CcSEcCtD
Aripiprazole—Urethral disorder—Doxorubicin—liver cancer	0.000181	0.000537	CcSEcCtD
Aripiprazole—Immune system disorder—Epirubicin—liver cancer	0.00018	0.000535	CcSEcCtD
Aripiprazole—Mediastinal disorder—Epirubicin—liver cancer	0.00018	0.000534	CcSEcCtD
Aripiprazole—Chills—Epirubicin—liver cancer	0.000179	0.000532	CcSEcCtD
Aripiprazole—Visual impairment—Doxorubicin—liver cancer	0.000178	0.000528	CcSEcCtD
Aripiprazole—Alopecia—Epirubicin—liver cancer	0.000176	0.000524	CcSEcCtD
Aripiprazole—Mental disorder—Epirubicin—liver cancer	0.000175	0.000519	CcSEcCtD
Aripiprazole—Erythema—Epirubicin—liver cancer	0.000174	0.000516	CcSEcCtD
Aripiprazole—Malnutrition—Epirubicin—liver cancer	0.000174	0.000516	CcSEcCtD
Aripiprazole—Eye disorder—Doxorubicin—liver cancer	0.000173	0.000512	CcSEcCtD
Aripiprazole—Tinnitus—Doxorubicin—liver cancer	0.000172	0.000511	CcSEcCtD
Aripiprazole—Cardiac disorder—Doxorubicin—liver cancer	0.000171	0.000509	CcSEcCtD
Aripiprazole—Flushing—Doxorubicin—liver cancer	0.000171	0.000509	CcSEcCtD
Aripiprazole—Flatulence—Epirubicin—liver cancer	0.000171	0.000508	CcSEcCtD
Aripiprazole—Tension—Epirubicin—liver cancer	0.00017	0.000506	CcSEcCtD
Aripiprazole—Dysgeusia—Epirubicin—liver cancer	0.00017	0.000505	CcSEcCtD
Aripiprazole—Nervousness—Epirubicin—liver cancer	0.000169	0.000501	CcSEcCtD
Aripiprazole—Back pain—Epirubicin—liver cancer	0.000168	0.000499	CcSEcCtD
Aripiprazole—Angiopathy—Doxorubicin—liver cancer	0.000167	0.000497	CcSEcCtD
Aripiprazole—Muscle spasms—Epirubicin—liver cancer	0.000167	0.000496	CcSEcCtD
Aripiprazole—Immune system disorder—Doxorubicin—liver cancer	0.000167	0.000495	CcSEcCtD
Aripiprazole—Mediastinal disorder—Doxorubicin—liver cancer	0.000166	0.000494	CcSEcCtD
Aripiprazole—Chills—Doxorubicin—liver cancer	0.000166	0.000492	CcSEcCtD
Aripiprazole—Vision blurred—Epirubicin—liver cancer	0.000164	0.000486	CcSEcCtD
Aripiprazole—Alopecia—Doxorubicin—liver cancer	0.000163	0.000485	CcSEcCtD
Aripiprazole—Mental disorder—Doxorubicin—liver cancer	0.000162	0.00048	CcSEcCtD
Aripiprazole—Ill-defined disorder—Epirubicin—liver cancer	0.000161	0.000479	CcSEcCtD
Aripiprazole—Malnutrition—Doxorubicin—liver cancer	0.000161	0.000477	CcSEcCtD
Aripiprazole—Erythema—Doxorubicin—liver cancer	0.000161	0.000477	CcSEcCtD
Aripiprazole—Anaemia—Epirubicin—liver cancer	0.000161	0.000477	CcSEcCtD
Aripiprazole—Agitation—Epirubicin—liver cancer	0.00016	0.000474	CcSEcCtD
Aripiprazole—Flatulence—Doxorubicin—liver cancer	0.000158	0.00047	CcSEcCtD
Aripiprazole—Tension—Doxorubicin—liver cancer	0.000158	0.000468	CcSEcCtD
Aripiprazole—Dysgeusia—Doxorubicin—liver cancer	0.000157	0.000467	CcSEcCtD
Aripiprazole—Malaise—Epirubicin—liver cancer	0.000157	0.000465	CcSEcCtD
Aripiprazole—Nervousness—Doxorubicin—liver cancer	0.000156	0.000464	CcSEcCtD
Aripiprazole—Vertigo—Epirubicin—liver cancer	0.000156	0.000463	CcSEcCtD
Aripiprazole—Syncope—Epirubicin—liver cancer	0.000156	0.000463	CcSEcCtD
Aripiprazole—Leukopenia—Epirubicin—liver cancer	0.000155	0.000462	CcSEcCtD
Aripiprazole—Back pain—Doxorubicin—liver cancer	0.000155	0.000462	CcSEcCtD
Aripiprazole—Muscle spasms—Doxorubicin—liver cancer	0.000155	0.000459	CcSEcCtD
Aripiprazole—Palpitations—Epirubicin—liver cancer	0.000153	0.000456	CcSEcCtD
Aripiprazole—Loss of consciousness—Epirubicin—liver cancer	0.000153	0.000453	CcSEcCtD
Aripiprazole—Cough—Epirubicin—liver cancer	0.000152	0.00045	CcSEcCtD
Aripiprazole—Vision blurred—Doxorubicin—liver cancer	0.000151	0.00045	CcSEcCtD
Aripiprazole—Convulsion—Epirubicin—liver cancer	0.00015	0.000447	CcSEcCtD
Aripiprazole—Hypertension—Epirubicin—liver cancer	0.00015	0.000445	CcSEcCtD
Aripiprazole—Ill-defined disorder—Doxorubicin—liver cancer	0.000149	0.000443	CcSEcCtD
Aripiprazole—Anaemia—Doxorubicin—liver cancer	0.000149	0.000441	CcSEcCtD
Aripiprazole—Arthralgia—Epirubicin—liver cancer	0.000148	0.000439	CcSEcCtD
Aripiprazole—Chest pain—Epirubicin—liver cancer	0.000148	0.000439	CcSEcCtD
Aripiprazole—Myalgia—Epirubicin—liver cancer	0.000148	0.000439	CcSEcCtD
Aripiprazole—Agitation—Doxorubicin—liver cancer	0.000148	0.000439	CcSEcCtD
Aripiprazole—Anxiety—Epirubicin—liver cancer	0.000147	0.000438	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000147	0.000436	CcSEcCtD
Aripiprazole—Discomfort—Epirubicin—liver cancer	0.000146	0.000434	CcSEcCtD
Aripiprazole—Malaise—Doxorubicin—liver cancer	0.000145	0.00043	CcSEcCtD
Aripiprazole—Dry mouth—Epirubicin—liver cancer	0.000145	0.000429	CcSEcCtD
Aripiprazole—Vertigo—Doxorubicin—liver cancer	0.000144	0.000429	CcSEcCtD
Aripiprazole—Syncope—Doxorubicin—liver cancer	0.000144	0.000428	CcSEcCtD
Aripiprazole—Leukopenia—Doxorubicin—liver cancer	0.000144	0.000427	CcSEcCtD
Aripiprazole—Confusional state—Epirubicin—liver cancer	0.000143	0.000424	CcSEcCtD
Aripiprazole—Palpitations—Doxorubicin—liver cancer	0.000142	0.000422	CcSEcCtD
Aripiprazole—Anaphylactic shock—Epirubicin—liver cancer	0.000142	0.000421	CcSEcCtD
Aripiprazole—Oedema—Epirubicin—liver cancer	0.000142	0.000421	CcSEcCtD
Aripiprazole—Loss of consciousness—Doxorubicin—liver cancer	0.000141	0.00042	CcSEcCtD
Aripiprazole—Infection—Epirubicin—liver cancer	0.000141	0.000418	CcSEcCtD
Aripiprazole—Cough—Doxorubicin—liver cancer	0.00014	0.000416	CcSEcCtD
Aripiprazole—Shock—Epirubicin—liver cancer	0.000139	0.000414	CcSEcCtD
Aripiprazole—Convulsion—Doxorubicin—liver cancer	0.000139	0.000414	CcSEcCtD
Aripiprazole—Nervous system disorder—Epirubicin—liver cancer	0.000139	0.000413	CcSEcCtD
Aripiprazole—Thrombocytopenia—Epirubicin—liver cancer	0.000139	0.000412	CcSEcCtD
Aripiprazole—Hypertension—Doxorubicin—liver cancer	0.000139	0.000412	CcSEcCtD
Aripiprazole—Tachycardia—Epirubicin—liver cancer	0.000138	0.000411	CcSEcCtD
Aripiprazole—Skin disorder—Epirubicin—liver cancer	0.000138	0.000409	CcSEcCtD
Aripiprazole—Hyperhidrosis—Epirubicin—liver cancer	0.000137	0.000407	CcSEcCtD
Aripiprazole—Chest pain—Doxorubicin—liver cancer	0.000137	0.000406	CcSEcCtD
Aripiprazole—Myalgia—Doxorubicin—liver cancer	0.000137	0.000406	CcSEcCtD
Aripiprazole—Arthralgia—Doxorubicin—liver cancer	0.000137	0.000406	CcSEcCtD
Aripiprazole—Anxiety—Doxorubicin—liver cancer	0.000136	0.000405	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000136	0.000404	CcSEcCtD
Aripiprazole—Discomfort—Doxorubicin—liver cancer	0.000135	0.000401	CcSEcCtD
Aripiprazole—Anorexia—Epirubicin—liver cancer	0.000135	0.000401	CcSEcCtD
Aripiprazole—Dry mouth—Doxorubicin—liver cancer	0.000134	0.000397	CcSEcCtD
Aripiprazole—Hypotension—Epirubicin—liver cancer	0.000132	0.000393	CcSEcCtD
Aripiprazole—Confusional state—Doxorubicin—liver cancer	0.000132	0.000393	CcSEcCtD
Aripiprazole—Anaphylactic shock—Doxorubicin—liver cancer	0.000131	0.00039	CcSEcCtD
Aripiprazole—Oedema—Doxorubicin—liver cancer	0.000131	0.00039	CcSEcCtD
Aripiprazole—Infection—Doxorubicin—liver cancer	0.00013	0.000387	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000129	0.000384	CcSEcCtD
Aripiprazole—Shock—Doxorubicin—liver cancer	0.000129	0.000383	CcSEcCtD
Aripiprazole—Nervous system disorder—Doxorubicin—liver cancer	0.000129	0.000382	CcSEcCtD
Aripiprazole—Thrombocytopenia—Doxorubicin—liver cancer	0.000128	0.000381	CcSEcCtD
Aripiprazole—Insomnia—Epirubicin—liver cancer	0.000128	0.000381	CcSEcCtD
Aripiprazole—Tachycardia—Doxorubicin—liver cancer	0.000128	0.00038	CcSEcCtD
Aripiprazole—Skin disorder—Doxorubicin—liver cancer	0.000127	0.000378	CcSEcCtD
Aripiprazole—Paraesthesia—Epirubicin—liver cancer	0.000127	0.000378	CcSEcCtD
Aripiprazole—Hyperhidrosis—Doxorubicin—liver cancer	0.000127	0.000377	CcSEcCtD
Aripiprazole—Dyspnoea—Epirubicin—liver cancer	0.000126	0.000375	CcSEcCtD
Aripiprazole—Somnolence—Epirubicin—liver cancer	0.000126	0.000374	CcSEcCtD
Aripiprazole—Anorexia—Doxorubicin—liver cancer	0.000125	0.000371	CcSEcCtD
Aripiprazole—Dyspepsia—Epirubicin—liver cancer	0.000125	0.000371	CcSEcCtD
Aripiprazole—Decreased appetite—Epirubicin—liver cancer	0.000123	0.000366	CcSEcCtD
Aripiprazole—Hypotension—Doxorubicin—liver cancer	0.000123	0.000364	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Epirubicin—liver cancer	0.000122	0.000363	CcSEcCtD
Aripiprazole—Fatigue—Epirubicin—liver cancer	0.000122	0.000363	CcSEcCtD
Aripiprazole—Constipation—Epirubicin—liver cancer	0.000121	0.00036	CcSEcCtD
Aripiprazole—Pain—Epirubicin—liver cancer	0.000121	0.00036	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000119	0.000355	CcSEcCtD
Aripiprazole—Insomnia—Doxorubicin—liver cancer	0.000119	0.000352	CcSEcCtD
Aripiprazole—Paraesthesia—Doxorubicin—liver cancer	0.000118	0.00035	CcSEcCtD
Aripiprazole—Dyspnoea—Doxorubicin—liver cancer	0.000117	0.000347	CcSEcCtD
Aripiprazole—Feeling abnormal—Epirubicin—liver cancer	0.000117	0.000347	CcSEcCtD
Aripiprazole—Somnolence—Doxorubicin—liver cancer	0.000117	0.000346	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Epirubicin—liver cancer	0.000116	0.000344	CcSEcCtD
Aripiprazole—Dyspepsia—Doxorubicin—liver cancer	0.000115	0.000343	CcSEcCtD
Aripiprazole—Decreased appetite—Doxorubicin—liver cancer	0.000114	0.000339	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000113	0.000336	CcSEcCtD
Aripiprazole—Fatigue—Doxorubicin—liver cancer	0.000113	0.000336	CcSEcCtD
Aripiprazole—Urticaria—Epirubicin—liver cancer	0.000113	0.000334	CcSEcCtD
Aripiprazole—Pain—Doxorubicin—liver cancer	0.000112	0.000333	CcSEcCtD
Aripiprazole—Constipation—Doxorubicin—liver cancer	0.000112	0.000333	CcSEcCtD
Aripiprazole—Body temperature increased—Epirubicin—liver cancer	0.000112	0.000333	CcSEcCtD
Aripiprazole—Abdominal pain—Epirubicin—liver cancer	0.000112	0.000333	CcSEcCtD
Aripiprazole—Feeling abnormal—Doxorubicin—liver cancer	0.000108	0.000321	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Doxorubicin—liver cancer	0.000107	0.000319	CcSEcCtD
Aripiprazole—Hypersensitivity—Epirubicin—liver cancer	0.000104	0.00031	CcSEcCtD
Aripiprazole—Urticaria—Doxorubicin—liver cancer	0.000104	0.000309	CcSEcCtD
Aripiprazole—Abdominal pain—Doxorubicin—liver cancer	0.000104	0.000308	CcSEcCtD
Aripiprazole—Body temperature increased—Doxorubicin—liver cancer	0.000104	0.000308	CcSEcCtD
Aripiprazole—Asthenia—Epirubicin—liver cancer	0.000102	0.000302	CcSEcCtD
Aripiprazole—Pruritus—Epirubicin—liver cancer	0.0001	0.000298	CcSEcCtD
Aripiprazole—Diarrhoea—Epirubicin—liver cancer	9.7e-05	0.000288	CcSEcCtD
Aripiprazole—Hypersensitivity—Doxorubicin—liver cancer	9.66e-05	0.000287	CcSEcCtD
Aripiprazole—Asthenia—Doxorubicin—liver cancer	9.41e-05	0.000279	CcSEcCtD
Aripiprazole—Dizziness—Epirubicin—liver cancer	9.37e-05	0.000278	CcSEcCtD
Aripiprazole—Pruritus—Doxorubicin—liver cancer	9.28e-05	0.000276	CcSEcCtD
Aripiprazole—Vomiting—Epirubicin—liver cancer	9.01e-05	0.000268	CcSEcCtD
Aripiprazole—Diarrhoea—Doxorubicin—liver cancer	8.97e-05	0.000267	CcSEcCtD
Aripiprazole—Rash—Epirubicin—liver cancer	8.94e-05	0.000265	CcSEcCtD
Aripiprazole—Dermatitis—Epirubicin—liver cancer	8.93e-05	0.000265	CcSEcCtD
Aripiprazole—Headache—Epirubicin—liver cancer	8.88e-05	0.000264	CcSEcCtD
Aripiprazole—Dizziness—Doxorubicin—liver cancer	8.67e-05	0.000258	CcSEcCtD
Aripiprazole—Nausea—Epirubicin—liver cancer	8.42e-05	0.00025	CcSEcCtD
Aripiprazole—Vomiting—Doxorubicin—liver cancer	8.34e-05	0.000248	CcSEcCtD
Aripiprazole—Rash—Doxorubicin—liver cancer	8.27e-05	0.000246	CcSEcCtD
Aripiprazole—Dermatitis—Doxorubicin—liver cancer	8.26e-05	0.000245	CcSEcCtD
Aripiprazole—Headache—Doxorubicin—liver cancer	8.22e-05	0.000244	CcSEcCtD
Aripiprazole—Nausea—Doxorubicin—liver cancer	7.79e-05	0.000231	CcSEcCtD
Aripiprazole—DRD3—Signaling Pathways—KRAS—liver cancer	5.37e-06	3.78e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—HRAS—liver cancer	5.37e-06	3.78e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CDKN1A—liver cancer	5.36e-06	3.77e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CCND1—liver cancer	5.36e-06	3.77e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CTNNB1—liver cancer	5.36e-06	3.77e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—JUN—liver cancer	5.34e-06	3.76e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CCND1—liver cancer	5.34e-06	3.76e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—HRAS—liver cancer	5.33e-06	3.75e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—JUN—liver cancer	5.33e-06	3.75e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—HMOX1—liver cancer	5.33e-06	3.75e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—VEGFA—liver cancer	5.33e-06	3.75e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CTNNB1—liver cancer	5.3e-06	3.73e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—PIK3CA—liver cancer	5.3e-06	3.73e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—TP53—liver cancer	5.3e-06	3.73e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MMP9—liver cancer	5.3e-06	3.72e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—MYC—liver cancer	5.29e-06	3.72e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—HRAS—liver cancer	5.29e-06	3.72e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	5.29e-06	3.72e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MMP9—liver cancer	5.28e-06	3.72e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TGFB1—liver cancer	5.28e-06	3.71e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CDKN1A—liver cancer	5.28e-06	3.71e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—STAT3—liver cancer	5.27e-06	3.71e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MMP9—liver cancer	5.27e-06	3.7e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CDKN1A—liver cancer	5.26e-06	3.7e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CD—liver cancer	5.26e-06	3.7e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MMP9—liver cancer	5.25e-06	3.69e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CDKN1A—liver cancer	5.25e-06	3.69e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—PIK3CA—liver cancer	5.25e-06	3.69e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—MYC—liver cancer	5.25e-06	3.69e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—VEGFA—liver cancer	5.24e-06	3.69e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MAPK8—liver cancer	5.23e-06	3.68e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TGFB1—liver cancer	5.23e-06	3.68e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CDKN1A—liver cancer	5.23e-06	3.68e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—HRAS—liver cancer	5.22e-06	3.67e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—AKT1—liver cancer	5.22e-06	3.67e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	5.2e-06	3.66e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MMP9—liver cancer	5.2e-06	3.66e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—ALB—liver cancer	5.19e-06	3.65e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—STAT3—liver cancer	5.19e-06	3.65e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MMP9—liver cancer	5.18e-06	3.65e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CDKN1A—liver cancer	5.18e-06	3.64e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	5.17e-06	3.63e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MAPK8—liver cancer	5.15e-06	3.62e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	5.15e-06	3.62e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—IL6—liver cancer	5.14e-06	3.62e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MAPK8—liver cancer	5.14e-06	3.61e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—HRAS—liver cancer	5.14e-06	3.61e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—IL6—liver cancer	5.14e-06	3.61e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—AKT1—liver cancer	5.14e-06	3.61e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—liver cancer	5.13e-06	3.61e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—AKT1—liver cancer	5.12e-06	3.6e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—PIK3CA—liver cancer	5.12e-06	3.6e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MAPK8—liver cancer	5.12e-06	3.6e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—AKT1—liver cancer	5.11e-06	3.59e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MAPK8—liver cancer	5.11e-06	3.59e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—IL6—liver cancer	5.1e-06	3.59e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CASP3—liver cancer	5.1e-06	3.59e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—AKT1—liver cancer	5.09e-06	3.58e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL2—liver cancer	5.09e-06	3.58e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—liver cancer	5.08e-06	3.57e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—HRAS—liver cancer	5.07e-06	3.57e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—IL6—liver cancer	5.06e-06	3.56e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MYC—liver cancer	5.06e-06	3.56e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MAPK8—liver cancer	5.06e-06	3.56e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TGFB1—liver cancer	5.05e-06	3.55e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—AKT1—liver cancer	5.04e-06	3.55e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MAPK8—liver cancer	5.04e-06	3.55e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MYC—liver cancer	5.04e-06	3.54e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—AKT1—liver cancer	5.03e-06	3.54e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TGFB1—liver cancer	5.03e-06	3.54e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—PIK3CA—liver cancer	5e-06	3.52e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—IL6—liver cancer	5e-06	3.51e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—PIK3CA—liver cancer	4.97e-06	3.5e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—GSTM1—liver cancer	4.96e-06	3.49e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCND1—liver cancer	4.96e-06	3.49e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CD—liver cancer	4.96e-06	3.49e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—JUN—liver cancer	4.95e-06	3.48e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—PIK3CA—liver cancer	4.93e-06	3.47e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—IL6—liver cancer	4.92e-06	3.46e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	4.91e-06	3.46e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—HRAS—liver cancer	4.9e-06	3.45e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MYC—liver cancer	4.9e-06	3.45e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—KRAS—liver cancer	4.89e-06	3.44e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—ALB—liver cancer	4.89e-06	3.44e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TGFB1—liver cancer	4.89e-06	3.44e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—HRAS—liver cancer	4.85e-06	3.41e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—IL6—liver cancer	4.85e-06	3.41e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—KRAS—liver cancer	4.85e-06	3.41e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—liver cancer	4.84e-06	3.4e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—VEGFA—liver cancer	4.83e-06	3.4e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MYC—liver cancer	4.82e-06	3.39e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MMP9—liver cancer	4.82e-06	3.39e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TGFB1—liver cancer	4.81e-06	3.38e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	4.8e-06	3.38e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—STAT3—liver cancer	4.78e-06	3.37e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—liver cancer	4.77e-06	3.36e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—VEGFA—liver cancer	4.75e-06	3.34e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—VEGFA—liver cancer	4.74e-06	3.34e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—AKT1—liver cancer	4.74e-06	3.34e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—AKT1—liver cancer	4.74e-06	3.33e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—VEGFA—liver cancer	4.73e-06	3.33e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—VEGFA—liver cancer	4.71e-06	3.32e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—AKT1—liver cancer	4.71e-06	3.31e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—STAT3—liver cancer	4.71e-06	3.31e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CYP1A1—liver cancer	4.71e-06	3.31e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—STAT3—liver cancer	4.7e-06	3.3e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—IL6—liver cancer	4.69e-06	3.3e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MAPK8—liver cancer	4.69e-06	3.3e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—STAT3—liver cancer	4.68e-06	3.29e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—KRAS—liver cancer	4.68e-06	3.29e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—AKT1—liver cancer	4.67e-06	3.29e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—VEGFA—liver cancer	4.67e-06	3.28e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—STAT3—liver cancer	4.67e-06	3.28e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—VEGFA—liver cancer	4.66e-06	3.27e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—KRAS—liver cancer	4.66e-06	3.27e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—IL6—liver cancer	4.65e-06	3.27e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—HRAS—liver cancer	4.63e-06	3.25e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—STAT3—liver cancer	4.62e-06	3.25e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—STAT3—liver cancer	4.61e-06	3.24e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—AKT1—liver cancer	4.61e-06	3.24e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CB—liver cancer	4.58e-06	3.22e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—HRAS—liver cancer	4.56e-06	3.21e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—AKT1—liver cancer	4.54e-06	3.19e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—KRAS—liver cancer	4.53e-06	3.18e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—PIK3CA—liver cancer	4.49e-06	3.16e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—AKT1—liver cancer	4.48e-06	3.15e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—KRAS—liver cancer	4.46e-06	3.13e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—PIK3CA—liver cancer	4.45e-06	3.13e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MYC—liver cancer	4.45e-06	3.13e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TGFB1—liver cancer	4.44e-06	3.12e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—IL6—liver cancer	4.43e-06	3.11e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—PIK3CA—liver cancer	4.4e-06	3.1e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—MTHFR—liver cancer	4.39e-06	3.09e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MYC—liver cancer	4.37e-06	3.08e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—IL6—liver cancer	4.37e-06	3.07e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MYC—liver cancer	4.37e-06	3.07e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TGFB1—liver cancer	4.36e-06	3.07e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TGFB1—liver cancer	4.35e-06	3.06e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MYC—liver cancer	4.35e-06	3.06e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—liver cancer	4.35e-06	3.06e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TGFB1—liver cancer	4.34e-06	3.05e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MYC—liver cancer	4.34e-06	3.05e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—AKT1—liver cancer	4.33e-06	3.05e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TGFB1—liver cancer	4.33e-06	3.04e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—VEGFA—liver cancer	4.33e-06	3.04e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CB—liver cancer	4.32e-06	3.04e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—liver cancer	4.31e-06	3.03e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PPARA—liver cancer	4.3e-06	3.03e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—PIK3CA—liver cancer	4.3e-06	3.02e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MYC—liver cancer	4.3e-06	3.02e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—AKT1—liver cancer	4.29e-06	3.01e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TGFB1—liver cancer	4.29e-06	3.01e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MYC—liver cancer	4.28e-06	3.01e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—STAT3—liver cancer	4.28e-06	3.01e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—PIK3CA—liver cancer	4.28e-06	3.01e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TGFB1—liver cancer	4.27e-06	3.01e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—AKT1—liver cancer	4.18e-06	2.94e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—PIK3CA—liver cancer	4.16e-06	2.93e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—liver cancer	4.16e-06	2.93e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—HRAS—liver cancer	4.16e-06	2.92e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—liver cancer	4.14e-06	2.91e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—HRAS—liver cancer	4.12e-06	2.9e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—KRAS—liver cancer	4.11e-06	2.89e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	4.09e-06	2.88e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—AKT1—liver cancer	4.08e-06	2.87e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—AKT1—liver cancer	4.06e-06	2.86e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—KRAS—liver cancer	4.04e-06	2.84e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PIK3CA—liver cancer	4.04e-06	2.84e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—KRAS—liver cancer	4.03e-06	2.84e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—AKT1—liver cancer	4.03e-06	2.83e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—liver cancer	4.02e-06	2.83e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—KRAS—liver cancer	4.02e-06	2.83e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—KRAS—liver cancer	4.01e-06	2.82e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MYC—liver cancer	3.98e-06	2.8e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—IL6—liver cancer	3.98e-06	2.8e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—HRAS—liver cancer	3.98e-06	2.8e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TGFB1—liver cancer	3.97e-06	2.79e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—KRAS—liver cancer	3.97e-06	2.79e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—liver cancer	3.96e-06	2.79e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—KRAS—liver cancer	3.96e-06	2.78e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—HRAS—liver cancer	3.96e-06	2.78e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—IL6—liver cancer	3.94e-06	2.77e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—HRAS—liver cancer	3.85e-06	2.71e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—IL6—liver cancer	3.81e-06	2.68e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HRAS—liver cancer	3.79e-06	2.66e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—IL6—liver cancer	3.79e-06	2.66e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—PIK3CA—liver cancer	3.77e-06	2.65e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—PIK3CA—liver cancer	3.71e-06	2.61e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PIK3CA—liver cancer	3.71e-06	2.61e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PIK3CA—liver cancer	3.7e-06	2.6e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PIK3CA—liver cancer	3.69e-06	2.6e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CG—liver cancer	3.69e-06	2.59e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—IL6—liver cancer	3.68e-06	2.59e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PIK3CA—liver cancer	3.68e-06	2.59e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—KRAS—liver cancer	3.68e-06	2.59e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—AKT1—liver cancer	3.67e-06	2.58e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—liver cancer	3.65e-06	2.57e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PIK3CA—liver cancer	3.65e-06	2.56e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—AKT1—liver cancer	3.64e-06	2.56e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	3.64e-06	2.56e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—IL6—liver cancer	3.63e-06	2.55e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—AKT1—liver cancer	3.6e-06	2.53e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—liver cancer	3.59e-06	2.53e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—liver cancer	3.59e-06	2.52e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—liver cancer	3.57e-06	2.51e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—liver cancer	3.56e-06	2.51e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PPARG—liver cancer	3.56e-06	2.5e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—liver cancer	3.53e-06	2.48e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—liver cancer	3.52e-06	2.47e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—AKT1—liver cancer	3.51e-06	2.47e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—AKT1—liver cancer	3.49e-06	2.46e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HRAS—liver cancer	3.49e-06	2.46e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—HRAS—liver cancer	3.44e-06	2.42e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HRAS—liver cancer	3.43e-06	2.41e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HRAS—liver cancer	3.42e-06	2.4e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HRAS—liver cancer	3.41e-06	2.4e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—AKT1—liver cancer	3.4e-06	2.39e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	3.38e-06	2.38e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HRAS—liver cancer	3.37e-06	2.37e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HRAS—liver cancer	3.36e-06	2.37e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—AKT1—liver cancer	3.34e-06	2.35e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—IL6—liver cancer	3.34e-06	2.35e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—AKT1—liver cancer	3.3e-06	2.32e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—IL6—liver cancer	3.29e-06	2.31e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—IL6—liver cancer	3.28e-06	2.31e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—IL6—liver cancer	3.27e-06	2.3e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—liver cancer	3.27e-06	2.3e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—IL6—liver cancer	3.26e-06	2.29e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CD—liver cancer	3.24e-06	2.28e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—IL6—liver cancer	3.23e-06	2.27e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—IL6—liver cancer	3.22e-06	2.26e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ALB—liver cancer	3.2e-06	2.25e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HRAS—liver cancer	3.13e-06	2.2e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—AKT1—liver cancer	3.08e-06	2.17e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—AKT1—liver cancer	3.03e-06	2.13e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—AKT1—liver cancer	3.03e-06	2.13e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—AKT1—liver cancer	3.02e-06	2.13e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—AKT1—liver cancer	3.02e-06	2.12e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—AKT1—liver cancer	3.01e-06	2.12e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL6—liver cancer	2.99e-06	2.1e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—AKT1—liver cancer	2.98e-06	2.1e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—AKT1—liver cancer	2.97e-06	2.09e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CB—liver cancer	2.82e-06	1.99e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CA—liver cancer	2.79e-06	1.97e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—AKT1—liver cancer	2.76e-06	1.94e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CA—liver cancer	2.63e-06	1.85e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—AKT1—liver cancer	2.28e-06	1.61e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—AKT1—liver cancer	2.15e-06	1.51e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CA—liver cancer	1.72e-06	1.21e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—AKT1—liver cancer	1.41e-06	9.89e-06	CbGpPWpGaD
